Efficacy, safety, and use of snake antivenoms in the United States☆☆☆
To access this article, please choose from the options below
☆ Dr. Dart and Mr. McNally were clinical investigators in the trials of the experimental antivenom described in the text and were paid speakers in the symposium “Advances in the Management of Snakebite” that was sponsored by Savage Laboratories.
☆☆ Address for reprints: Richard C. Dart, MD, PhD, Rocky Mountain Poison and Drug Center, 1010 Yosemite Circle, Denver, CO 80230; 303-739-1100, fax 303-739-1119;,E-mail rdart@rmpdc.org .
PII: S0196-0644(01)65378-2
doi:10.1067/mem.2001.113372
© 2001 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Out-of-hospital and interhospital management of crotaline snakebite
- Role of surgical intervention in the management of crotaline snake envenomation
- Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies
- Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 2. Guidelines for clinical management with crotaline fab antivenom
